Climb Bio, Inc.

Climb Bio, Inc. is a clinical-stage biotechnology company dedicated to developing high-impact, disease-modifying medicines for individuals suffering from immune-mediated diseases. Headquartered in Wellesley Hills, Massachusetts, the company focuses on addressing significant unmet medical needs within this therapeutic area.

The company's pipeline features two primary investigational therapies: budoprutug and CLYM116. Budoprutug is an anti-CD19 monoclonal antibody designed to treat a range of B-cell mediated diseases, currently in Phase 2 clinical trials for primary membranous nephropathy (pMN) and immune thrombocytopenia (ITP), and a Phase 1b clinical trial for systemic lupus erythematosus (SLE). CLYM116 is an anti-APRIL monoclonal antibody in preclinical development for the treatment of IgA nephropathy (IgAN) and other B-cell mediated conditions.

In recent developments, Climb Bio, Inc. successfully raised $110 million through a private placement in April 2026 to advance its pipeline. The U.S. Food and Drug Administration (FDA) granted Fast Track Designation to budoprutug for primary membranous nephropathy, aiming to expedite its development and review. The company also announced initial Phase 1b data for budoprutug in ITP and initial Phase 1 safety data for CLYM116 in June 2026. Led by CEO Aoife M. Brennan, MD, Climb Bio, Inc. continues to position itself as a key player in the biotechnology sector, particularly in the development of therapies for immune-mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and rebranded to Climb Bio, Inc. in October 2024 following the acquisition of Tenet Medicines, Inc.